EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Magle Chemoswed Holding Ab (MAGLE) fair value: what the stock is really worth

As of Oct 12, 2026: fair value of Magle Chemoswed Holding Ab SEK 0.66, price SEK 0.40, upside +65.0%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE · ISIN SE0014401014

MC Thin data Oct 3, 2026

Magle Chemoswed Holding Ab

MAGLE · ST

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

Fair value kr 0.6600 · Strongly undervalued (+65.0%)
Expensive Growth (revenue 5y +14.7 %/yr in SEK)
Moderate debt
Quality 28/100
Loss-making · -94.9% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 12/100
Thin data
Watch Magle Chemoswed Holding Ab for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 46.00 kr 0.3100 Fair Value kr 0.6600 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range kr 0.3100 – kr 46.00 · fair‑value band kr 0.4900 – kr 0.9900 · the kr 0.4000 price screens below the kr 0.6600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow Magle Chemoswed Holding in your weekly email

Every Wednesday you see whether Magle Chemoswed Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden.

Show more

Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures. In addition, it is developing EmboCept M for the treatment of benign prostatic hyperplasia; EmboCept L for the treatment of uterine fibroids; SmartGel II, an advanced wound care hydrogel for the removal and prevention of wound biofilm; and SmartBone, an advanced formulation of microspheres in combination with active ingredients for stimulation of bone growth in surgical implant procedures. The company was founded in 1944 and is based in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.

Stock analysis

Magle Chemoswed Holding Ab (MAGLE) currently trades at kr 0.4000, while our model-based Fair Value estimate is kr 0.6600, implying the stock looks roughly 39.4% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: kr 0.4900 (bear) to kr 0.9900 (bull), the price of kr 0.4000 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Magle Chemoswed Holding Ab reported revenue of 283M SEK in FY2025 versus 132M SEK in FY2021, a compound +21.0%/yr. Reported net income was −160M SEK in FY2025.

Key figures

Market cap 10.0M SEK (≈ $1.0M) · P/S ratio 0.04 · EPS (TTM) kr −12.72 · Net margin −56.5% · Return on equity −66.3% · Return on assets (EBIT) 0.2% · Operating margin −20.3% · Revenue (TTM) 276M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 98% below its 52-week high and 29% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 65%, MAGLE screens cheaper than that median.

Fair Value models

Bear kr 0.4900 Fair Value kr 0.6600 Bull kr 0.9900
Price kr 0.4000 · Upside +65.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 0.4924 kr 0.6600 kr 0.9854 54
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.4924 kr 0.6600 kr 0.9854 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 28/100

Of which business quality 28 · Market factors (momentum, volatility) 15

Profitability 12
Margins and returns on capital today
Quality Growth 36
Are margins and returns improving?
Cashflow 25
Earnings quality: real cash, not paper profit
Fin. Strength 31
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+19.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.3% (2020) → −48.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch MAGLE, get fair value alerts →

Compare Magle Chemoswed Holding Ab with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 588 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside +65.0% · Top 25%
Profitability
Return on assets −9.0% · Below median
Net margin (TTM) −94.9% · Bottom 25%
Operating margin (TTM) −20.3% · Bottom 25%
Growth and dividend
Revenue growth 39.2% · Top 25%
Balance sheet
Debt / equity 0.73× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

EV/EBITDA 6.2× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)63 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73% vs MAGLE
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10% vs MAGLE
Samsung Biologics Co 207940 1,219,000 KRW 1,340,900 KRW +10% vs MAGLE
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10% vs MAGLE
CSL Limited CSL A$181.46 A$179.90 −1% vs MAGLE
argenx SE ARGX $959.49 $918.60 −4% vs MAGLE
Alnylam Pharmaceuticals, Inc ALNY $232.68 $217.88 −6% vs MAGLE
BeOne Medicines AG ONC $354.47 $280.94 −21% vs MAGLE
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58% vs MAGLE
Royalty Pharma plc RPRX $56.93 $19.01 −67% vs MAGLE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Magle Chemoswed Holding Ab · Fair Value
kr 0.6600 +39%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Magle Chemoswed Holding Ab Fair Value". https://www.fairvalue-calculator.com/stock/MAGLE

Frequently asked questions

Is Magle Chemoswed Holding Ab (MAGLE) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of kr 0.6600 versus a price of kr 0.4000, about +65% upside (undervalued).
What is the fair value of MAGLE?
Our model-based fair value for Magle Chemoswed Holding Ab is kr 0.6600 (as of Oct 3, 2026), built from audited fundamentals. The current price: kr 0.4000.
What is the quality score of MAGLE?
Magle Chemoswed Holding Ab has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Magle Chemoswed Holding Ab (MAGLE)?
Our model-based price target is the fair value of kr 0.6600 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario kr 0.4900, optimistic scenario kr 0.9900. It is a calculation from audited fundamentals, not an analyst target.
What is the Magle Chemoswed Holding Ab stock forecast for 2026?
Our models put fair value at kr 0.6600, about +65% upside versus a price of kr 0.4000 (undervalued). Cautious scenario kr 0.4900, optimistic scenario kr 0.9900. The calculation is refreshed regularly with new filings.
What is the revenue of Magle Chemoswed Holding Ab (MAGLE)?
Magle Chemoswed Holding Ab reported trailing-twelve-month revenue of about 276M SEK (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Magle Chemoswed Holding Ab (MAGLE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Magle Chemoswed Holding Ab it is kr 0.6600 per share (as of Oct 3, 2026), against a price of kr 0.4000. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Magle Chemoswed Holding Ab stock overvalued or undervalued in 2026?
As of Oct 3, 2026, MAGLE trades below its calculated fair value: price kr 0.4000, fair value kr 0.6600, a gap of about +65% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MAGLE?
No. The price is what the market pays today (kr 0.4000); the fair value is what the company's own numbers justify (kr 0.6600). For Magle Chemoswed Holding Ab the two are kr 0.2600 per share apart. That gap is exactly why we show both numbers side by side.
How much is Magle Chemoswed Holding Ab worth?
The market values Magle Chemoswed Holding Ab at about 10.0M SEK (market capitalisation, as of Oct 3, 2026). Per share that is kr 0.4000; our models calculate a fair value of kr 0.6600 per share.
What do the bullish and bearish scenarios say about MAGLE?
Our models span a range for Magle Chemoswed Holding Ab: cautious scenario kr 0.4900, base kr 0.6600, optimistic kr 0.9900 per share (as of Oct 3, 2026, price kr 0.4000). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Magle Chemoswed Holding Ab (MAGLE)?
Balance-sheet figures for Magle Chemoswed Holding Ab (as of Oct 3, 2026): return on equity −66.3%, debt of 0.73 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is MAGLE from its 52-week high?
Magle Chemoswed Holding Ab trades at kr 0.4000, about 98% below its 52-week high of kr 20.80 and 29% above the low of kr 0.3100 (as of Oct 12, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.6600 is for.
Which stocks are comparable to Magle Chemoswed Holding Ab?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Magle Chemoswed Holding Ab stock attractive at the current price?
The data as of Oct 3, 2026: price kr 0.4000, calculated fair value kr 0.6600 (+65%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MAGLE calculated?
We run Magle Chemoswed Holding Ab through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.6600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Magle Chemoswed Holding Ab currently trades 39 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Magle Chemoswed Holding Ab (MAGLE)?
The closing price on Oct 12, 2026 was kr 0.4000. Our model-based fair value is kr 0.6600, about +65% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Magle Chemoswed Holding Ab right now?
The large discount to fair value meets weak quality (28/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (kr 0.4900). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.4900 to kr 0.9900) leaves room in how you read the outcome.

Key figures of Magle Chemoswed Holding Ab

How large is the market capitalisation of Magle Chemoswed Holding Ab (MAGLE)?
The market capitalisation of Magle Chemoswed Holding Ab is 10.0M SEK (≈ $1.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Magle Chemoswed Holding Ab (MAGLE)?
The price-to-sales ratio of Magle Chemoswed Holding Ab is 0.04 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Magle Chemoswed Holding Ab (MAGLE)?
Earnings per share at Magle Chemoswed Holding Ab are kr −12.72. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Magle Chemoswed Holding Ab (MAGLE)?
The net margin of Magle Chemoswed Holding Ab is −56.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Magle Chemoswed Holding Ab (MAGLE)?
The return on equity (ROE) of Magle Chemoswed Holding Ab is −66.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Magle Chemoswed Holding Ab (MAGLE)?
On an EBIT basis the return on assets of Magle Chemoswed Holding Ab is 0.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Magle Chemoswed Holding Ab (MAGLE)?
The operating margin of Magle Chemoswed Holding Ab is −20.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Magle Chemoswed Holding Ab (MAGLE)?
Revenue at Magle Chemoswed Holding Ab is growing +39.2% versus a year earlier (3y avg +24.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Magle Chemoswed Holding Ab (MAGLE)?
Earnings per share at Magle Chemoswed Holding Ab are growing −83.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Magle Chemoswed Holding Ab (MAGLE) generate?
The free cash flow of Magle Chemoswed Holding Ab is −31.9M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Magle Chemoswed Holding Ab (MAGLE) carry?
The net debt of Magle Chemoswed Holding Ab is 333M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Magle Chemoswed Holding Ab in the live analysis

One click puts Magle Chemoswed Holding Ab on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.